Last reviewed · How we verify

TAF based regimen (TBR)

ViiV Healthcare · Phase 3 active Small molecule

TAF based regimen (TBR) is a Nucleotide reverse transcriptase inhibitor (NtRTI) Small molecule drug developed by ViiV Healthcare. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy).

TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication.

TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy).

At a glance

Generic nameTAF based regimen (TBR)
SponsorViiV Healthcare
Drug classNucleotide reverse transcriptase inhibitor (NtRTI)
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

TAF is a prodrug of tenofovir that achieves higher intracellular concentrations with lower systemic exposure compared to TDF (tenofovir disoproxil fumarate). When used as part of a combination antiretroviral regimen (TBR), it inhibits HIV reverse transcriptase, preventing conversion of viral RNA to DNA and blocking viral replication. TAF-based regimens typically include additional antiretroviral agents such as integrase inhibitors or protease inhibitors to provide potent combination therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TAF based regimen (TBR)

What is TAF based regimen (TBR)?

TAF based regimen (TBR) is a Nucleotide reverse transcriptase inhibitor (NtRTI) drug developed by ViiV Healthcare, indicated for HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy).

How does TAF based regimen (TBR) work?

TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication.

What is TAF based regimen (TBR) used for?

TAF based regimen (TBR) is indicated for HIV-1 infection in treatment-naïve and treatment-experienced adults (as part of combination antiretroviral therapy).

Who makes TAF based regimen (TBR)?

TAF based regimen (TBR) is developed by ViiV Healthcare (see full ViiV Healthcare pipeline at /company/viiv-healthcare).

What drug class is TAF based regimen (TBR) in?

TAF based regimen (TBR) belongs to the Nucleotide reverse transcriptase inhibitor (NtRTI) class. See all Nucleotide reverse transcriptase inhibitor (NtRTI) drugs at /class/nucleotide-reverse-transcriptase-inhibitor-ntrti.

What development phase is TAF based regimen (TBR) in?

TAF based regimen (TBR) is in Phase 3.

What are the side effects of TAF based regimen (TBR)?

Common side effects of TAF based regimen (TBR) include Nausea, Diarrhea, Headache, Fatigue, Elevated creatinine.

What does TAF based regimen (TBR) target?

TAF based regimen (TBR) targets HIV reverse transcriptase and is a Nucleotide reverse transcriptase inhibitor (NtRTI).

Related